SAGE Therapeutics (SAGE)
Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics today and set a price target of $52.00. The company’s shares closed last Wednesday at $45.49, close to its 52-week low of $39.77.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -0.6% and a 48.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Arcutis Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $76.33 average price target.
G1 Therapeutics (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics, with a price target of $78.00. The company’s shares closed last Wednesday at $13.93, close to its 52-week low of $10.81.
According to TipRanks.com, White is a 5-star analyst with an average return of 28.3% and a 44.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.
Currently, the analyst consensus on G1 Therapeutics is a Strong Buy with an average price target of $58.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.